Clinical investigation of helical tomotherapy (TOMO) in unresectable thymic carcinomas with pleural dissemination

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061028

Enrollment

Unknown

Registered

2022-06-15

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thymic tumors

Interventions

1:hemical tomotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Pathological diagnosis of thymoma or thymic carcinoma; 2. Mmultiple pleural dissemination confirmed by radiology (initially diagnosed or pleural recurrence after previous definitive treatment); 3. Not suitable for complete resection; 4. Aged 18-75 years; 5. KPS > 80; 6. Enough cardiac-pulmonary function reservation.

Exclusion criteria

Exclusion criteria: 1. Ipsilateral pleural radiotherapy has been given within 1 year; 2. Complicated with other tumors or serious medical diseases that affect prognosis; 3. The performance status cann't endure RT.

Design outcomes

Primary

Measure	Time frame
objective response rate;local-contral time;	—

Secondary

Measure	Time frame
progression-free survival;	—

Countries

China

Contacts

Public ContactDu Shisuo

Zhongshan Hospital, Fudan University

du.shisuo@zs-hospital.sh.cn+86 13621830381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026